Testing BGC515 Capsules in Advanced Solid Tumors
Tests the BGC515 capsule in adults with advanced solid tumors, including mesothelioma.
Key facts
- Who runs it
- BridGene Biosciences Inc.
- Where
- Houston, United StatesSee the site
- Trial code
- Registry title
- A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 103 people, planned
- Started
- 27 Jun 2024
- Expected to end
- Dec 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- BGC515
- Record updated
- 9 August 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced solid tumors, such as mesothelioma or epithelioid hemangioendothelioma, whose disease got worse after standard treatment or who cannot have it.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Locally advanced or metastatic mesothelioma, epithelioid hemangioendothelioma (EHE), or other advanced solid tumors, confirmed by tissue or cell tests. At least one measurable lesion. In the expansion phase, other solid tumors need Hippo signaling pathway abnormalities.
- Earlier treatment
- Disease got worse or standard treatment was not tolerated, or the person refuses or has no access to standard treatment. No previous or current TEAD inhibitors.
- Biomarker or test result
- Hippo signaling pathway abnormalities are needed in the expansion phase for solid tumors other than mesothelioma and EHE.
Main reasons for not taking part
- Previous or current use of TEAD inhibitors
- Severe or unstable systemic disease, or unstable or symptomatic brain or spinal cord (CNS) metastasis
- Clinically significant cardiovascular disease
- Pregnant or breastfeeding women
- Allergy to BGC515 or any of its ingredients
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Having signed the written Informed Consent Form
- Male or female aged ≥18 years
- Life expectancy ≥12 weeks
- Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1
- Dose escalation phase: Histologically or cytologically confirmed locally advanced or metastatic mesothelioma (MM), epithelioid hemangioendothelioma (EHE), or other advanced solid tumors who have experienced progressive disease or treatment intolerability after receiving the standard-of-care, or refuse to receive or have no access to the standard-of-care
- Dose expansion phase: Histologically or cytologically confirmed locally advanced or metastatic MM, EHE, etc. regardless of Hippo signaling pathway abnormalities, or other advanced solid tumors with Hippo signaling pathway abnormalities, who have experienced progressive disease or treatment intolerability after receiving the standard-of-care, or refuse to receive or have no access to the standard-of-care
- At least one measurable lesion
Who cannot take part
- Previous or current use of transcriptional enhanced associate domain (TEAD) inhibitors
- Inadequate wash-out of prior therapies described per protocol
- Patients with severe or unstable systemic disease, unstable or symptomatic Central Nervous System (CNS) metastasis
- Clinically significant cardiovascular disease as defined in the protocol
- Hypersensitivity to the active pharmaceutical ingredient or any excipient of BGC515
- Serious systemic diseases or laboratory abnormalities or other conditions that, at the Investigator's discretion, will make it unsuitable for the patient to participate in this clinical trial
- Women who are pregnant or breastfeeding
- Study staff member or relative of a study staff member directly related to this clinical trial, or a subordinate of the Investigator in this trial or an employee of the Sponsor, though not directly related to this trial
Where in United States
- MD Anderson Cancer CenterHouston, United StatesContact: Ileana GutierrezTaking people
About the trial
What the trial wants to find out
The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.
The 2 groups in the trial
- Dose EscalationTreatment being tested
BGC515 Capsules will be administered orally in 21 day cycles, once daily (QD). Patients will be enrolled into escalating dose levels during the Dose Escalation Phase to determine the Maximum Tolerated Dose (MTD) and the Recommended Dose(s) for Expansion (RDE).
Treatment: BGC515
- Dose ExpansionTreatment being tested
BGC515 Capsules will be administered orally in 21 day cycles at MTD/RDE defined dose,once daily (QD), in patients with malignant mesothelioma (MM), epithelioid hemangioendothelioma (EHE), or other advanced solid tumors.
Treatment: BGC515
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Patients With Advanced Solid Tumors
- Plain-language title
- Testing BGC515 Capsules in Advanced Solid TumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 August 2024